ArticleOncogene2000
Analysis of p73 in human borderline and invasive ovarian tumor.
Article in Oncogene, 2000. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
19 citing papers in PubMed, 67 citations in OpenAlex.
- Transcription Factor p73 Is a Predictor of Platinum Resistance and Promotes Aggressive Epithelial Ovarian Cancers.International journal of molecular sciences · 2025Article
- Re-appraising the evidence for the source, regulation and function of p53-family isoforms.Nucleic acids research · 2024Review
- Requirement for TP73 and genetic alterations originating from its intragenic super-enhancer in adult T-cell leukemia.Leukemia · 2022Article
- Evasion of anti-growth signaling: A key step in tumorigenesis and potential target for treatment and prophylaxis by natural compounds.Seminars in cancer biology · 2015Review
- Preclinical activity of combined HDAC and KDM1A inhibition in glioblastoma.Neuro-oncology · 2015Article
- N-(phosphonacetyl)-L-aspartate induces TAp73-dependent apoptosis by modulating multiple Bcl-2 proteins: potential for cancer therapy.Oncogene · 2013Article
- p53 Family: Role of Protein Isoforms in Human Cancer.Journal of nucleic acids · 2012Article
- p73 in Cancer.Genes & cancer · 2011Article
- Prognostic value of increase in transcript levels of Tp73 DeltaEx2-3 isoforms in low-grade glioma patients.British journal of cancer · 2006Article
- Article
- The role of p73 in hematological malignancies.Leukemia · 2006Review
- Article
- Characterization of p73 functional domains necessary for transactivation and growth suppression.Oncogene · 2003Article
- DeltaNp73, a dominant-negative inhibitor of wild-type p53 and TAp73, is up-regulated in human tumors.The Journal of experimental medicine · 2002Article
- E7 proteins from oncogenic human papillomavirus types transactivate p73: role in cervical intraepithelial neoplasia.British journal of cancer · 2002Article
- p73 is over-expressed in vulval cancer principally as the Delta 2 isoform.British journal of cancer · 2001Article
- p73 Overexpression increases VEGF and reduces thrombospondin-1 production: implications for tumor angiogenesis.Oncogene · 2001Article
- p73 is not mutated in meningiomas as determined with a functional yeast assay but p73 expression increases with tumor grade.Brain pathology (Zurich, Switzerland) · 2001Article
- Detection of p73 antibodies in patients with various types of cancer: immunological characterization.British journal of cancer · 2001Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
p73 is a novel gene that has high sequence homology and similar gene structure to the tumor suppressor gene p53. We analysed p73 in seven ovarian carcinoma cell lines and a total of 63 human borderline and invasive ovarian tumor samples. Loss of heterozygosity at this locus was observed in 50% of invasive tumors but in none of the borderline tumors. Biallelic expression of the gene was observed in the heterozygous tumor tissues. Direct sequencing and single-strand conformation polymorphism analyses of the p73 cDNA sequence homologous to the highly mutatable region of p53 did not reveal any mutations. When compared to the primary cultures of normal human ovarian surface epithelial cells and immortalized cell lines, four of the seven ovarian carcinoma cell lines, 71% of the invasive tumors, and 92% of the borderline tumor tissues express elevated levels of p73 transcript. Except for the OVCA3 cell line, Western blot analysis of the nuclear extracts prepared from the cell lines showed concordant levels of p73 protein. Our analysis also demonstrated the expression of a spliced variant of p73 transcript with the omission of exon 2 solely in the cancer cell lines and invasive tumor tissues. This exon 2-spliced transcript would give rise to a truncated p73 protein without the N-terminal transactivation domain. In reminiscence of the dominant negative phenotype of the N-terminal truncated variants of another p53-related gene, p63, the expression of the truncated p73 variant form in ovarian tumors may play an important role in the pathogenesis of ovarian cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.